Rachel E Rau

List of Publications by Year
in descending order

80 papers	1,817 citations	394421 19 h-index	276875 41 g-index
84 all docs	84 docs citations	84 times ranked	3450 citing authors

#	Article	IF	Citations
1	DNMT3A in haematological malignancies. Nature Reviews Cancer, 2015, 15, 152-165.	28.4	379
2	The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood, 2007, 110, 979-985.	1.4	193
3	Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematological Oncology, 2009, 27, 171-181.	1.7	127
4	DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood, 2016, 128, 971-981.	1.4	107
5	DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell, 2016, 29, 922-934.	16.8	107
6	Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. American Journal of Infection Control, 2004, 32, 189-195.	2.3	98
7	Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Chemistry and Biology, 2013, 20, 1352-1363.	6.0	72
8	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood and Cancer, 2020, 67, e28073.	1.5	52
9	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget, 2014, 5, 8947-8958.	1.8	51
10	Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology, 2016, 44, 740-744.	0.4	48
11	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2018, 65, e26873.	1.5	48
12	Fatal Infection Caused by Cupriavidus gilardii in a Child with Aplastic Anemia. Journal of Clinical Microbiology, 2010, 48, 1005-1007.	3.9	39
13	<scp>MLL</scp>â€rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with <scp>CXCR</scp>4 antagonism. British Journal of Haematology, 2013, 160, 785-797.	2.5	39
14	A KLF4-DYRK2â€“mediated pathway regulating self-renewal in CML stem cells. Blood, 2019, 134, 1960-1972.	1.4	38
15	Triad of Severe Abdominal Pain, Inappropriate Antidiuretic Hormone Secretion, and Disseminated Varicella-Zoster Virus Infection Preceding Cutaneous Manifestations After Hematopoietic Stem Cell Transplantation. Pediatric Infectious Disease Journal, 2008, 27, 265-268.	2.0	37
16	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Experimental Hematology, 2014, 42, 101-113.e5.	0.4	32
17	The genomics of acute myeloid leukemia in children. Cancer and Metastasis Reviews, 2020, 39, 189-209.	5.9	26
18	Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in Pediatrics, 0, 10, .	1.9	22

#	Article	IF	Citations
19	Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368.	2.5	21
20	Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?. Pediatric Blood and Cancer, 2021, 68, e29169.	1.5	18
21	A phase 1 study of eribulin mesylate (E7389), a novel microtubuleâ€targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood and Cancer, 2018, 65, e27066.	1.5	15
22	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e132-e143.	3.8	15
23	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. Haematologica, 2022, 107, 887-898.	3.5	15
24	Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2020, 10, 1129.	2.8	13
25	Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model. Blood, 2014, 124, 3572-3572.	1.4	12
26	Constitutive loss of DNMT3A causes morbid obesity through misregulation of adipogenesis. ELife, 0, 11, .	6.0	12
27	Prevention of mercaptopurineâ€induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. Pediatric Blood and Cancer, 2019, 66, e27577.	1.5	11
28	Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26487.	1.5	10
29	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. Blood, 2021, 138, 2304-2304.	1.4	10
30	Incidence and predictors of treatmentâ€related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28063.	1.5	9
31	Prognostic impact of minimal residual disease at the end of consolidation in NCI standardâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e28929.	1.5	9
32	Sustained remission with azacitidine monotherapy and an aberrant precursor Bâ€lymphoblast population in juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27905.	1.5	7
33	Beyond KIT in CBF-AML: chromatin and cohesin. Blood, 2016, 127, 2370-2371.	1.4	6
34	Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Advances, 2021, 5, 3876-3890.	5.2	6
35	Using genomics to define pediatric blood cancers and inform practice. Hematology American Society of Hematology Education Program, 2018, 2018, 286-300.	2.5	6
36	Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget, 2018, 9, 35313-35326.	1.8	6

#	Article	IF	Citations
37	Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. Blood Advances, 2021, 5, 4992-5001.	5.2	6
38	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.	1.4	5
39	Klinefelter syndrome and 47,<scp>XYY</scp> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	2.5	4
40	Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS ONE, 2018, 13, e0197408.	2.5	4
41	A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. Journal of Clinical Oncology, 2020, 38, TPS7568-TPS7568.	1.6	4
42	Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases. Blood, 2021, 138, 2307-2307.	1.4	4
43	Murine Models of Acute Myeloid Leukemia. Frontiers in Oncology, 0, 12, .	2.8	4
44	CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3. Blood, 2017, 130, 385-386.	1.4	3
45	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S8-S11.	0.4	3
46	An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. Leukemia, 2021, 35, 1777-1781.	7.2	3
47	A viral cause of APL. Blood, 2021, 138, 1653-1655.	1.4	3
48	Ponatinib use in two pediatric patients with relapsed Phâ€‰+â€‰ALL with ABL1 kinase domain mutations. Pediatric Hematology and Oncology, 2019, 36, 514-519.	0.8	2
49	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. Blood, 2015, 126, 1312-1312.	1.4	2
50	Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. Blood, 2019, 134, 3789-3789.	1.4	2
51	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. Blood, 2018, 132, 549-549.	1.4	1
52	Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.. Blood, 2006, 108, 221-221.	1.4	1
53	Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. Blood, 2010, 116, 145-145.	1.4	1
54	Dnmt3a-Deletion Accelerates FLT3-ITD Malignancies In Mice By Hypomethylation Of Enhancer Sites and Activating Stem Cell Programs; Implications For Therapy. Blood, 2013, 122, 595-595.	1.4	1

#	Article	IF	Citations
55	A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations. Blood, 2015, 126, 312-312.	1.4	1
56	A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314).. Journal of Clinical Oncology, 2016, 34, 2567-2567.	1.6	1
57	Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, 7033-7033.	1.6	1
58	Efficacy and safety of intramuscular (IM) recombinant Erwinia asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Childrenâ€™s Oncology Group (COG) AALL1931 study.. Journal of Clinical Oncology, 2022, 40, 7001-7001.	1.6	1
59	50 Years Ago in The Journal of Pediatrics. Journal of Pediatrics, 2017, 183, 140.	1.8	0
60	3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. Journal of Clinical and Translational Science, 2019, 3, 30-31.	0.6	0
61	Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning. Cell Stem Cell, 2019, 24, 511-512.	11.1	0
62	SIRPAssing other xenograft murine models?. Blood, 2020, 135, 1612-1614.	1.4	0
63	Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S99-S101.	0.4	0
64	Predictors of Acute Intracranial Pathology Identified by Computerized Tomography in Children with Sickle Cell Disease.. Blood, 2006, 108, 3798-3798.	1.4	0
65	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. Blood, 2009, 114, 2742-2742.	1.4	0
66	Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. Blood, 2011, 118, 1410-1410.	1.4	0
67	Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. Blood, 2011, 118, 2437-2437.	1.4	0
68	Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Blood, 2013, 122, 171-171.	1.4	0
69	Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis. Blood, 2013, 122, 1269-1269.	1.4	0
70	DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia. Blood, 2014, 124, 614-614.	1.4	0
71	Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors. Blood, 2015, 126, 1277-1277.	1.4	0
72	Aberrant Precursor B Lymphoid Blast Population in a Patient with Juvenile Myelomonocytic Leukemia. Blood, 2016, 128, 5557-5557.	1.4	0

#	Article	IF	Citations
73	Leukemia Fusion Gene Detection in the Clinical Molecular Laboratory Using RNA-Based Targeted Next-Generation Sequencing. Blood, 2016, 128, 4074-4074.	1.4	0
74	Abstract 145: Pharmacologic inhibition of SIAH2 stabilizes DYRK2 and inhibits survival and self-renewal in chronic myeloid leukemia (CML) leukemic stem cells. , 2018, , .		0
75	Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage. Blood, 2018, 132, 173-173.	1.4	0
76	A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3792-3792.	1.4	0
77	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. Blood, 2019, 134, 2586-2586.	1.4	0
78	Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with KMT2A Rearranged Acute Myeloid Leukemia. Blood, 2020, 136, 34-34.	1.4	0
79	Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin. Blood, 2020, 136, 10-11.	1.4	0
80	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 7000-7000.	1.6	0